Nippon Shinyaku Co Ltd bought $15.0M of Capricor Therapeutics (CAPR)
Executed Sep 20 2024, disclosed Sep 24 2024, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 24 2024), the stock returned +138.9% (delay-adjusted); from the execution session (Sep 20 2024), +278.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Nippon Shinyaku Co Ltd (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in Capricor Therapeutics, Inc. (CAPR). Across 1 priced purchase filing, the average 21-session return was +278.0% from execution and +138.9% from disclosure (delay-adjusted; derived). The median gap between execution and disclosure was 4 days.
Healthcare · Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based th…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→